Business Wire
19 Oct 2025, 08:15 UTC · 48w ago
Verdict
Headline takes no side. We score VSTM +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Verastem Oncology announced positive updated efficacy and safety data for GFH375 (VS-7375), an oral KRAS G12D inhibitor, in patients with advanced pancreatic ductal adenocarcinoma.
So whatPositive clinical data for a hard-to-treat cancer like pancreatic ductal adenocarcinoma typically serves as a significant positive catalyst for biotech valuations.
More positive than 92% of claims this week
The Phase 1/2 monotherapy study was conducted in China by partner GenFleet Therapeutics and included 59 heavily pre-treated patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company announced positive updated efficacy and safety data for its KRAS G12D inhibitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−13.3%
Price is moving against the score
$7.99 vs $9.22 close before publication (Oct 17) · not market-adjusted
VSTM chart →